Literature DB >> 23893151

Haplotype structures and functional polymorphic variants of the drug target enzyme aromatase (CYP19A1) in South Indian population.

Gurusamy Umamaheswaran1, Steven Aibor Dkhar, Sekar Kalaivani, Raj Anjana, Mohan Revathy, Mohammad Jaharamma, Kulumani Mahadevan Lakshmi Shree, Dharanipragada Kadambari, Chandrasekaran Adithan.   

Abstract

CYP19A1 gene product aromatase (CYP19A1) is a 58-kDa protein and belongs to the member of the cytochrome P450 superfamily, which facilitates the bioconversion of estrogens from androgens. Single-nucleotide polymorphisms (SNPs) of CYP19A1 affect the activity of the enzyme and have been implicated in the association of estrogen-dependent disease, prognosis, therapeutic efficacy, and toxicity of third-generation aromatase inhibitors (AIs). Based on ethnicity, the frequency distribution of CYP19A1 alleles will differ, and until now, no data are available for Indians. Using qRT-PCR with TaqMan assays, the frequencies of functionally important polymorphic variants of CYP19A1 gene were determined in 163 healthy subjects of South Indian origin. The observed frequencies of the CYP19A1 minor alleles for the SNPs rs4646 (T), rs10046 (T), rs700519 (T), rs700518 (G), rs727479 (G), rs4775936 (T), rs10459592 (G), rs749292 (A), rs6493497 (T), and rs7176005 (A) are 41.1 (35.8-46.4), 20.0 (15.6-24.3), 33.7 (28.6-38.9), 17.8 (13.6-21.9), 25.8 (21.0-30.5), 19.9 (15.6-24.3), 33.7 (28.6-38.9), 24.9 (20.2-29.5), 35.9 (30.7-41.1), and 35.9 (30.7-41.1), respectively. Strong linkage disequilibrium existed between CYP19A1 SNPs, and sixteen different haplotype structures with a frequency >1% were derived from all the 10 SNPs tested. The most common being the haplotype (H1) GCTATCTGTG with a frequency of about 17.8%. Gender-specific assessment showed significant difference in the allele frequency for rs749292 (p < 0.04), and greater inter-ethnic variation was detected in the distribution of CYP19A1 variants except for rs727479. Our results could provide preliminary insight for further pharmacogenetic investigations of AIs as well as for subsequent molecular epidemiological studies on the contribution of these variants to the occurrence and development of estrogen-dependent disease in South Indians.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23893151     DOI: 10.1007/s12032-013-0665-x

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  44 in total

1.  Effect of CYP19 rs6493497 and rs7176005 haplotype status on in vivo aromatase transcription, plasma and tissue estrogen levels in postmenopausal women.

Authors:  Anne Hege Straume; Stian Knappskog; Per Eystein Lønning
Journal:  J Steroid Biochem Mol Biol       Date:  2011-09-16       Impact factor: 4.292

2.  Genetic polymorphisms of drug-metabolizing phase I enzymes CYP2E1, CYP2A6 and CYP3A5 in South Indian population.

Authors:  D Krishnakumar; Umamaheswaran Gurusamy; Kayathri Dhandapani; A Surendiran; Ruchi Baghel; Ritushree Kukreti; Reneega Gangadhar; Ushakiran Prayaga; S Manjunath; C Adithan
Journal:  Fundam Clin Pharmacol       Date:  2011-01-25       Impact factor: 2.748

3.  Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer.

Authors:  In Hae Park; Yeon-Su Lee; Keun Seok Lee; Sook-young Kim; Seung-Hyun Hong; Jaeheon Jeong; Hyewon Lee; Jungsil Ro; Byung-Ho Nam
Journal:  Cancer Chemother Pharmacol       Date:  2011-03-27       Impact factor: 3.333

4.  Variants in CYP17 and CYP19 cytochrome P450 genes are associated with onset of Alzheimer's disease in women with down syndrome.

Authors:  Constance Chace; Deborah Pang; Catherine Weng; Alexis Temkin; Simon Lax; Wayne Silverman; Warren Zigman; Michel Ferin; Joseph H Lee; Benjamin Tycko; Nicole Schupf
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

5.  Allelic variants of aromatase and the androgen and estrogen receptors: toward a multigenic model of prostate cancer risk.

Authors:  F Modugno; J L Weissfeld; D L Trump; J M Zmuda; P Shea; J A Cauley; R E Ferrell
Journal:  Clin Cancer Res       Date:  2001-10       Impact factor: 12.531

Review 6.  Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis.

Authors:  E R Simpson; M S Mahendroo; G D Means; M W Kilgore; M M Hinshelwood; S Graham-Lorence; B Amarneh; Y Ito; C R Fisher; M D Michael
Journal:  Endocr Rev       Date:  1994-06       Impact factor: 19.871

7.  CYP19 (aromatase) haplotypes and endometrial cancer risk.

Authors:  Randi A Paynter; Susan E Hankinson; Graham A Colditz; Peter Kraft; David J Hunter; Immaculata De Vivo
Journal:  Int J Cancer       Date:  2005-08-20       Impact factor: 7.396

8.  Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women.

Authors:  Christopher A Haiman; Laure Dossus; V Wendy Setiawan; Daniel O Stram; Alison M Dunning; Gilles Thomas; Michael J Thun; Demetrius Albanes; David Altshuler; Eva Ardanaz; Heiner Boeing; Julie Buring; Noël Burtt; Eugenia E Calle; Stephen Chanock; Françoise Clavel-Chapelon; Graham A Colditz; David G Cox; Heather Spencer Feigelson; Susan E Hankinson; Richard B Hayes; Brian E Henderson; Joel N Hirschhorn; Robert Hoover; David J Hunter; Rudolf Kaaks; Laurence N Kolonel; Loïc Le Marchand; Per Lenner; Eiliv Lund; Salvatore Panico; Petra H Peeters; Malcolm C Pike; Elio Riboli; Anne Tjonneland; Ruth Travis; Dimitrios Trichopoulos; Sholom Wacholder; Regina G Ziegler
Journal:  Cancer Res       Date:  2007-02-26       Impact factor: 12.701

9.  Association of two common single-nucleotide polymorphisms in the CYP19A1 locus and ovarian cancer risk.

Authors:  Marc T Goodman; Galina Lurie; Pamela J Thompson; Katharine E McDuffie; Michael E Carney
Journal:  Endocr Relat Cancer       Date:  2008-07-30       Impact factor: 5.678

10.  A single-nucleotide polymorphism in the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma.

Authors:  Ramon Colomer; Mariano Monzo; Ignasi Tusquets; Juli Rifa; José M Baena; Agusti Barnadas; Lourdes Calvo; Francisco Carabantes; Carmen Crespo; Montserrat Muñoz; Antonio Llombart; Arrate Plazaola; Rosa Artells; Monstsrrat Gilabert; Belen Lloveras; Emilio Alba
Journal:  Clin Cancer Res       Date:  2008-02-01       Impact factor: 12.531

View more
  4 in total

1.  Genotypic and allelic variability in CYP19A1 among populations of African and European ancestry.

Authors:  Athena Starlard-Davenport; Mohammed S Orloff; Ishwori Dhakal; Rosalind B Penney; Susan A Kadlubar
Journal:  PLoS One       Date:  2015-02-03       Impact factor: 3.240

2.  An assessment of the multifactorial profile of steroid-metabolizing enzymes and steroid receptors in the eutopic endometrium during moderate to severe ovarian endometriosis.

Authors:  G Anupa; Jai Bhagwan Sharma; Kallol K Roy; Jayasree Sengupta; Debabrata Ghosh
Journal:  Reprod Biol Endocrinol       Date:  2019-12-26       Impact factor: 5.211

3.  Genotype, allele and haplotype frequencies of four TCL1A gene polymorphisms associated with musculoskeletal toxicity in the South Indian descent.

Authors:  Gurusamy Umamaheswaran; Steven Aibor Dkhar; Annan Sudarsan Arun Kumar; Rao Katiboina Srinivasa; Dharanipragada Kadambari; Chandrasekaran Adithan
Journal:  Bioimpacts       Date:  2014-06-19

4.  Association of CYP19A1 and CYP1A2 genetic polymorphisms with type 2 diabetes mellitus risk in the Chinese Han population.

Authors:  Yafeng Yang; Ping Wang
Journal:  Lipids Health Dis       Date:  2020-08-19       Impact factor: 3.876

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.